(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 5.24% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Merck & Co's revenue in 2026 is $65,011,000,000.On average, 30 Wall Street analysts forecast MRK's revenue for 2026 to be $166,728,227,114,308, with the lowest MRK revenue forecast at $160,117,050,898,286, and the highest MRK revenue forecast at $175,109,636,004,478. On average, 29 Wall Street analysts forecast MRK's revenue for 2027 to be $175,762,347,493,270, with the lowest MRK revenue forecast at $162,179,025,828,788, and the highest MRK revenue forecast at $187,627,356,715,667.
In 2028, MRK is forecast to generate $187,968,546,812,081 in revenue, with the lowest revenue forecast at $175,119,525,572,490 and the highest revenue forecast at $207,025,744,371,205.